Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Nov 04, 2025
|
Exagen Inc. Reports Q3 2025 Earnings: Revenue $17.24 M, Net Loss $7.1 M
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
Advanced wound care devices are a key growth area via its wound care partnerships.
|
$218.14M |
$9.40
-9.57%
|
|
EPRX
Eupraxia Pharmaceuticals Inc.
Diffusphere is Eupraxia's proprietary drug-delivery platform enabling localized, extended-release formulation, a core product/technology they directly develop and apply to its pipeline candidates EP-104IAR and EP-104GI.
|
$216.94M |
$5.75
-5.50%
|
|
WALD
Waldencast plc
FDA-approved Obagi saypha MagIQ injectable gel indicates a dermal filler/medical device product line.
|
$216.83M |
$1.76
-0.28%
|
|
IVA
Inventiva S.A.
Inventiva's lanifibranor is an orally administered small-molecule therapeutic for MASH, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$215.16M |
$4.02
-1.95%
|
|
BSGM
BioSig Technologies, Inc.
BioSig's PURE EP Platform has direct cardiology device usage for electrophysiology procedures.
|
$215.15M |
N/A
|
|
XGN
Exagen Inc.
Exagen provides diagnostic testing services and operates lab facilities for autoimmune diagnostics.
|
$212.97M |
$11.13
-5.87%
|
|
PERF
Perfect Corp.
HD skin diagnostics deployed in aesthetic clinics, representing healthcare-oriented diagnostic software.
|
$212.86M |
$1.93
-7.66%
|
|
RNAC
Cartesian Therapeutics, Inc.
Lead platform is an autologous cell therapy using mRNA CAR-T, a direct cell-therapy product line.
|
$211.01M |
$7.80
-4.06%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
CRGX's core offerings are oncology CAR-T therapies (firi-cel, CRG-23), placing it in Biotech - Oncology.
|
$206.13M |
$4.47
|
|
QTRX
Quanterix Corporation
Quanterix directly manufactures and sells ultra-sensitive diagnostic instruments (Simoa platforms) used for biomarker detection in blood and other samples.
|
$205.41M |
$5.24
-1.04%
|
|
ELMD
Electromed, Inc.
Electromed manufactures the SmartVest Clearway airway clearance medical device, fitting the Medical Devices & Biometrics investable theme.
|
$201.69M |
$24.83
+3.24%
|
|
SNFCA
Security National Financial Corporation
Death care services (cemetery and mortuary) are a direct service offering aligned with healthcare services and facilities.
|
$200.41M |
$7.98
-1.48%
|
|
OSUR
OraSure Technologies, Inc.
OraSure's core offerings include diagnostic equipment such as OraQuick rapid tests and molecular diagnostics platforms.
|
$199.72M |
$2.58
-3.37%
|
|
NNOX
Nano-X Imaging Ltd.
Directly manufactures diagnostic imaging equipment used for disease detection and monitoring.
|
$199.56M |
$3.27
-3.96%
|
|
DERM
Journey Medical Corporation
Emrosi is an oral small molecule therapeutic (minocycline extended-release) and represents Journey Medical's flagship product launched in 2025.
|
$198.48M |
$8.84
+3.76%
|
|
TARA
Protara Therapeutics, Inc.
TARA-2.00 is a cell therapy platform, representing the company’s lead product modality.
|
$197.54M |
$4.68
-8.59%
|
|
NTHI
Neonc Technologies Holdings, Inc.
Directly produces oncology-focused biotech therapies; lead programs NEO100/NEO212 targeting brain cancers.
|
$193.88M |
$10.45
+2.55%
|
|
GNFT
Genfit S.A.
GENFIT's ELAFIBRONOR in Primary Biliary Cholangitis (PBC) represents a core liver-disease therapeutic offering.
|
$193.14M |
$3.89
+0.52%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$193.14M |
$1.45
-9.94%
|
|
CATX
Perspective Therapeutics, Inc.
Company directly develops and provides radiopharmaceuticals using alpha-emitting Lead-212 for targeted cancer therapy and diagnostic imaging via 203Pb in a theranostic approach.
|
$192.99M |
$2.36
-9.23%
|
|
MDWD
MediWound Ltd.
MediWound's core products are enzymatic proteins/enzymes (NexoBrid, EscharEx) used for wound debridement, aligning with Recombinant Proteins & Enzymes.
|
$192.57M |
$17.76
-3.06%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA's lead product Foralumab is a fully human monoclonal antibody therapeutic, placing the company in Monoclonal Antibody Therapeutics.
|
$191.74M |
$1.81
-2.69%
|
|
PLX
Protalix BioTherapeutics, Inc.
Protalix manufactures recombinant proteins/enzymes (e.g., Elelyso, Elfabrio) using its plant-based ProCellEx system.
|
$190.26M |
$2.35
-1.88%
|
|
UTMD
Utah Medical Products, Inc.
Filshie Clip System is a surgical device used in gynecologic procedures, directly aligning with UTMD's Filshie Clip product line.
|
$189.99M |
$57.82
-1.15%
|
|
HBB
Hamilton Beach Brands Holding Company
Home health monitoring devices tied to HealthBeacon’s at-home patient monitoring platform and subscription model.
|
$188.40M |
$14.21
+3.27%
|
|
CDXS
Codexis, Inc.
Codexis is pivoting to manufacturing RNAi therapeutics using the ECO Synthesis platform, directly targeting RNAi drug production.
|
$187.23M |
$2.17
-4.20%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$185.49M |
$1.55
-2.81%
|
|
STIM
Neuronetics, Inc.
NeuroStar Advanced Therapy System is a non-invasive neuromodulation device; the direct product of the company.
|
$182.32M |
$2.87
+3.43%
|
|
OABI
OmniAb, Inc.
OmniAb's core offering is the Antibody Discovery Platform enabling rapid generation of human antibodies through engineered transgenic animals and associated discovery tools.
|
$181.06M |
$1.49
+0.34%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$180.50M |
$16.26
-2.46%
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$180.03M |
$1.11
-5.93%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is an oncology-focused therapeutic developed by SELLAS, targeting cancer antigens (WT1) and used as an immunotherapy.
|
$178.60M |
$1.68
-6.15%
|
|
TLSI
TriSalus Life Sciences, Inc.
TriNav and related systems are vascular intervention devices used for embolization and targeted drug delivery.
|
$178.22M |
$4.73
+0.42%
|
Showing page 22 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
